Dermatology

Lawrence Eichenfield, MD, reacts to the FDA's acceptance of a supplemental New Drug Application for roflumilast cream 0.15% to treat atopic dermatitis (AD) in patients aged 6 years and older.

The FDA has accepted a supplemental New Drug Application (sNDA) for roflumilast cream 0.15% for the treatment of atopic dermatitis (AD) in children aged 6 years and up.

The FDA granted Priority Review to pz-cel following a phase 1/2 and a pivotal phase 3 study in which the treatment for recessive dystrophic epidermolysis bullosa (RDEB) demonstrated wound healing and pain reduction.

Of patients in the atopic dermatitis (AD) cohort, 36.6% developed at least 1 comorbidity amid follow-up compared to 28.5% in the non-AD reference cohort, investigators of a Sweden, nationwide, population-based cohort study found.

The topical gel is the first and only FDA-approved triple-combination, fixed-dose topical treatment for acne, and is set to be available in the first quarter of 2024, according to Bausch Health Companies Inc.

A healthy 13-year-old girl presented with a 1-month history of an asymptomatic, well-demarcated rash on her back and upper chest. The eruption consisted of discrete, dark brown papules that coalesced into large, flat-topped plaques with mild superficial scale and accentuation of skin markings. What's the diagnosis?

A rapid reduction in pruritis as early as 24 hours after first application was announced as new positive data from a pair of identical, phase 3 studies of tapinarof cream 1% in children as young as 2 years and adults with atopic dermatitis (AD).

Once-daily, topical roflumilast cream 0.3% has been approved by the FDA for children aged 6 to 11 years for the treatment of plaque psoriasis based on a data from a 4-week Maximal Usage Systemic Exposure study, and safety and efficacy data from a pair of phase 3 trials in adults.

Positive topline results from a pair of identical phase 3 trials support the submission of a supplemental New Drug Application to the FDA for Arcutis Biotherapeutics’ roflumilast cream 0.15%, a once-daily topical to treat mild to moderate atopic dermatitis (AD) in children 6 years or older.

Based on recent positive phase 3 results, Arcutis Biotherapeutics,. intends to submit a supplemental New Drug Application with the FDA for roflumilast cream 0.05% to treat mild to moderate atopic dermatitis in children aged 2 to 5 years.

Hair loss is a condition that is often distressing and difficult to treat, particularly in adolescents. Here’s what you should know.

In this Contemporary Pediatrics interview, Bernard A. Cohen, MD, discusses VP-102, approved by the FDA on July 22, 2023, to treat molluscum contagiosum in pediatric patients 2 years and up.

Peter Lio, MD, clinical assistant professor of dermatology and pediatrics at Northwestern University Feinberg School of Medicine in Chicago, Illinois, discusses the 2023 Society for Pediatric Dermatology Meeting held in Asheville, North Carolina, and what pearls to consider following the atopic dermatitis panel he took part in.

The fully online training program, the MOPD Foundations of Pediatric Dermatology Certificate Course, was created by the founders of the Masters of Pediatric Dermatology (MOPD) Symposium and includes lectures, presentations, and downloadable resources for clinicians.

Following the resubmission of a new drug application, the FDA has approved VP-102 to treat molluscum contagiosum, a contagious skin disease transmitted through direct skin-to-skin contact that primarily affects children.

You are called to the hospital nursery to evaluate a healthy full-term newborn boy who developed painful flaccid blisters and erosions on the tops of his feet and ankles shortly after birth. His mother had a history of similar recurrent skin lesions that healed with scarring. She also had oral and gastrointestinal tract involvement. What's the diagnosis?

The device is now the first of its kind to become available to pediatric patients.

In her presentation ‘Treatment of Eczema in Pediatric Patients Under 12 Years,’ Dr. Garza-Mayers spoke on considerations for atopic dermatitis management.

A new treatment for severe hair thinning for adolescents and adults offers hope for young people struggling with this highly visible disorder.

These new guidelines were developed to benefit younger patients with inflammatory skin diseases, and may be helpful given the inexpensive nature and general availability of the drug.

After 12 weeks of treatment, 55.8% of participants receiving IDP-126 experienced at least a 70% reduction from baseline in inflammatory and noninflammatory lesions

You are asked to evaluate a boy, aged 14 years, who presents with one week of tender, expanding, confluent, purple blisters on his swollen left thumb, extending under the thumbnail.. What is the diagnosis?

A previously healthy 2-week-old girl developed multiple, asymptomatic pustules on her scalp, forehead, eyelids, and upper cheeks. She has been growing and developing well with appropriate weight gain. What's the diagnosis?

New data indicates that increased risk for offspring in developing different disorders is associated with maternal alopecia areata exposure, expanding the available information on alopecia and maternal autoimmunity.

Family history, seasonal change, swimming, and several other factors can contribute to dry skin, according to the Society for Pediatric Dermatology.